| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 8, 2012FDA to Review World's First Insulin Pump with Threshold Suspend - Another Significant Step Toward the Artificial Pancreas
MINNEAPOLIS - June 8, 2012 -In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that it has filed the final module of its Pre-Market...
-
May 31, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 31, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs 33rd Annual...
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 23, 2012Grant to Partners In Health creates a program within the Rwandan Ministry of Health to provide planning assistance to six low-income countries in order to improve access to NCD care
MINNEAPOLIS--(BUSINESS WIRE)--May. 23, 2012-- In a continued commitment to help reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes, the...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 17, 2012Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from...
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 16, 2012Closure Ends Federal Civil and Criminal Investigations of the Company
MINNEAPOLIS--(BUSINESS WIRE)--May. 16, 2012-- Medtronic, Inc. (NYSE: MDT) today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...